JPWO2021012049A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021012049A5 JPWO2021012049A5 JP2022504181A JP2022504181A JPWO2021012049A5 JP WO2021012049 A5 JPWO2021012049 A5 JP WO2021012049A5 JP 2022504181 A JP2022504181 A JP 2022504181A JP 2022504181 A JP2022504181 A JP 2022504181A JP WO2021012049 A5 JPWO2021012049 A5 JP WO2021012049A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 44
- 150000003839 salts Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025001996A JP7758895B2 (ja) | 2019-07-22 | 2025-01-06 | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| US62/877,177 | 2019-07-22 | ||
| CAPCT/CA2019/051539 | 2019-10-30 | ||
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001996A Division JP7758895B2 (ja) | 2019-07-22 | 2025-01-06 | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022541825A JP2022541825A (ja) | 2022-09-27 |
| JPWO2021012049A5 true JPWO2021012049A5 (https=) | 2023-07-31 |
| JP2022541825A5 JP2022541825A5 (https=) | 2023-07-31 |
| JP7617076B2 JP7617076B2 (ja) | 2025-01-17 |
Family
ID=74192632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504181A Active JP7617076B2 (ja) | 2019-07-22 | 2020-07-22 | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
| JP2025001996A Active JP7758895B2 (ja) | 2019-07-22 | 2025-01-06 | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025001996A Active JP7758895B2 (ja) | 2019-07-22 | 2025-01-06 | Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (https=) |
| EP (1) | EP4003993A4 (https=) |
| JP (2) | JP7617076B2 (https=) |
| KR (1) | KR20220035925A (https=) |
| CN (1) | CN114174292B (https=) |
| AU (1) | AU2020317381A1 (https=) |
| BR (1) | BR112022000431A2 (https=) |
| CA (1) | CA3148278A1 (https=) |
| CO (1) | CO2022001853A2 (https=) |
| CR (1) | CR20220068A (https=) |
| EC (1) | ECSP22012347A (https=) |
| IL (1) | IL289763A (https=) |
| MX (1) | MX2022000854A (https=) |
| PH (1) | PH12022550156A1 (https=) |
| UA (1) | UA129807C2 (https=) |
| WO (1) | WO2021012049A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
| CA3164203A1 (en) * | 2019-12-11 | 2021-06-17 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors |
| BR112023022481A2 (pt) * | 2021-04-28 | 2024-02-15 | Repare Therapeutics Inc | Métodos de tratamento de cânceres com mutação de perda de função bialélica ou de superexpressão gênica |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
| KR20240041354A (ko) * | 2021-07-27 | 2024-03-29 | 릿츠뜨 메디시네스 엘티디 | 8-옥소-3-아자비시클로[3.2.1]옥탄계 화합물 또는 이의 염 및 이의 제조 방법과 용도 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| WO2025067111A1 (zh) * | 2023-09-27 | 2025-04-03 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3795573B1 (en) * | 2009-12-31 | 2022-07-06 | Hutchison Medipharma Limited | Certain triazolopyrazines, compositions thereof and methods of use therefor |
| JP5889875B2 (ja) * | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | アザインダゾール |
| ES2951688T3 (es) * | 2011-02-28 | 2023-10-24 | Epizyme Inc | Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2013095761A1 (en) * | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| RS61688B1 (sr) * | 2015-04-29 | 2021-05-31 | Janssen Pharmaceutica Nv | Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora |
| JP6873145B2 (ja) * | 2016-01-14 | 2021-05-19 | バイエル・ファルマ・アクティエンゲゼルシャフト | ５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン |
| CR20210281A (es) * | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| MX2022000854A (es) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc | Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr. |
-
2020
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en not_active Abandoned
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko not_active Ceased
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021012049A5 (https=) | ||
| CN101558040B (zh) | 用作蛋白激酶抑制剂的二氢吡啶衍生物 | |
| JP7715911B2 (ja) | 神経筋疾患の処置のためのピリダジノン化合物 | |
| EP2727918A1 (en) | Compounds and Compositions as Protein Kinase Inhibitors | |
| JP4881725B2 (ja) | Ｔｉｅ−２モジュレータと使用方法 | |
| RU2006134020A (ru) | Конденсированные производные пиразола | |
| JPWO1994014769A1 (ja) | Ｎ−置換インドール誘導体 | |
| JP2012508223A5 (https=) | ||
| AU2005335298C1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| JP2002541108A (ja) | 炎症性疾患治療用フタラジン誘導体 | |
| JP2005508967A5 (https=) | ||
| JP2016507502A5 (https=) | ||
| JPH083041A (ja) | ストレス関連障害治療剤 | |
| CN104884057A (zh) | 大麻素受体介导的化合物 | |
| JP2025081626A (ja) | ペンタミジンの類似体及びその使用 | |
| JP2018532790A5 (https=) | ||
| JPWO2020119819A5 (https=) | ||
| JPWO2008001929A1 (ja) | 炎症性腸疾患の処置剤 | |
| CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
| TW575571B (en) | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives | |
| JPWO2021262810A5 (https=) | ||
| CN105050602A (zh) | 作为pi3激酶抑制剂的吡啶化合物 | |
| US8530501B2 (en) | Salts and crystalline forms of a factor Xa inhibitor | |
| JPH01254665A (ja) | ジヒドロピリジン抗アレルギーおよび抗炎症剤 | |
| JP2962186B2 (ja) | ピペリジン誘導体及びそれを含有するセロトニン拮抗薬 |